Form D · Pharmaceuticals
Hemispherian AS
Oslo, Q8 · CIK 0001838780
Offering snapshot reported May 4, 2022 · SEC filing
- Reported sold
- $50K Offering amount: $50K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Apr 27, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 4, 2022 | Initial | $50,000 | No comparison | 2 | SEC filing |
| Jan 4, 2021 | Initial | $57,713 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c, 4a5
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-444332
Internationally, the total offering was NOK 12,500,000 (about USD 1,331,856). However, only shares with a total value of USD 50,000 were offered to two specific investors in the US. These investors also contributed in our previous financing round.
No commissions or finders' fees are paid.
Source: Form D, filed May 4, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Zeno Albisser | Executive |
| Anett Monika Diaz | Director |
| Dallas Christian Hack | Director |
| Steven John Powell | Director |
| Terezia Prikrylova | Promoter |
| Adam Brian Robertson | Promoter |
| Masha Paule Nathalie Legris Stromme | Director |
| Cecilie Stenstadvold Sverdrup | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
Gaustadalleen 21
Oslo, Q8, 0349
Oslo, Q8, 0349